AC Immune’s (ACIU) Buy Rating Reiterated at BTIG Research

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reiterated by BTIG Research in a note issued to investors on Wednesday, Benzinga reports. They currently have a $8.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 197.95% from the company’s previous close.

ACIU has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AC Immune in a report on Wednesday, August 5th. HC Wainwright reissued a “buy” rating on shares of AC Immune in a report on Monday, August 24th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, AC Immune currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

AC Immune Stock Performance

Shares of NASDAQ:ACIU traded down $0.15 during midday trading on Wednesday, hitting $2.69. The stock had a trading volume of 125,158 shares, compared to its average volume of 274,092. The company has a market capitalization of $273.25 million, a PE ratio of -4.97 and a beta of 1.60. The stock has a 50 day moving average price of $2.55 and a two-hundred day moving average price of $2.68. The company has a current ratio of 0.93, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. AC Immune has a 1 year low of $2.10 and a 1 year high of $4.00.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.13. The business had revenue of $18.67 million for the quarter, compared to the consensus estimate of $9.59 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. As a group, equities analysts predict that AC Immune will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of AC Immune

A number of institutional investors have recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership boosted its holdings in AC Immune by 8.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after buying an additional 30,035 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after buying an additional 176,701 shares in the last quarter. Finally, AXQ Capital LP purchased a new stake in AC Immune during the second quarter worth about $25,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

Key Stories Impacting AC Immune

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: Positive Phase 2 safety and immune-response data: Through week 100 of the VacSYn Phase 2 trial, ACI-7104 met all primary endpoints, was generally safe and well tolerated, and produced a 100% antibody response after three doses. Antibodies also penetrated the cerebrospinal fluid, with signals of target engagement—important evidence that the vaccine is reaching the central nervous system. AC Immune Phase 2 trial announcement
• Positive Sentiment: Analysts reaffirm bullish views: BTIG Research reiterated its Buy rating and set an $8 price target, implying substantial potential appreciation from the reference price of $2.71. H.C. Wainwright analyst Andrew Fein also maintained a Buy rating and $12 target, citing the VacSYn data as validation of AC Immune’s platform. BTIG Research rating H.C. Wainwright rating
• Neutral Sentiment: Development remains ongoing: The reported results primarily establish safety and immunogenicity, rather than demonstrating definitive clinical benefits for Parkinson’s patients. Part 2 of the trial is intended to assess clinical activity, and AC Immune expects to discuss the future development path with the FDA in early 2027. AC Immune Phase 2 results

AC Immune Company Profile

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.